Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast CancerDavid Miles, Gilles Romieu, Arlene Chan et al.|Journal of Clinical Oncology|2010Cited by 887
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtypeLorenzo Gerratana, Grazia Arpino, Debora Basile et al.|Cancer Treatment Reviews|2018Cited by 282
CDK 4/6 Inhibitors as Single Agent in Advanced Solid TumorsFrancesco Schettini, Lucia Del Mastro, Irene De Santo et al.|Frontiers in Oncology|2018Cited by 205
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trialLucia Del Mastro, Francesco Cognetti, Sabino De Placido et al.|The Lancet|2015Cited by 201
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysisMario Giuliano, Daniele Generali, Francesco Schettini et al.|The Lancet Oncology|2019Cited by 193